Briefcases -- All Litigations -- ZOFRAN MDL 2657 Brand and Generic (Ondansetron) Cases Included
ZOFRAN MDL 2657 Brand and Generic (Ondansetron) Cases Included
Case Files
News
Chat
Easy Button
Committees

Categories

  1. ZOFRAN MDL 2657 Master Long & Short Form Complaints and Plaintiff Fact Sheet
  2. Zofran MDL 2657 PTOs
  3. Zofran MDL About the Defendant Glaxo Smith Kline
  4. About Judge Dennis Saylor IV
  5. Zofran MDL Electronic Filing Link
  6. District Court of Massachusetts Link
  7. Zofran Intake Questionnaire Sample
  8. Defendants Motion to Consolidate and Transfer
  9. Educational Videos
  10. Zofran Evidence
  11. 50 State SOL Tolling For Minors
  12. Zofran MDL Steering Committee and Lead Counsel
  13. Zofran MDL 2657 Forms
  14. Zofran JMPL Transfer Order
  15. Zofran MDL Local Court Rules and Info
  16. State by State SOL Tolling for Minors
  17. Zofran Complaints Filed
  18. Zofran MDL 2657 Important Documents
  19. Zofran Settlement News
  20. Defendants Motion to Dismiss
  21. Zofran Master Case File Number
View All

Documents

  1. Zofran Qualifying Questions.docx
  2. ZOFRAN MDL 2657 MDL (2nd order) Approved Generic Joint Master Short Form Complaint 6-20-2016.pdf
  3. Zofran MDL CMO 8 Appointing Leadership.pdf
  4. PTO 9 Zofran Order Denying Defendants Summary Motion.pdf
  5. Zofran Judge Saylor Standing Order Inexperienced Attorneys.pdf
  6. ZOFRAN MDL 2657 MDL Approved Generic Joint Master Short Form Complaint 6-20-2016.pdf
  7. ZOFRAN MDL 2657 MDL Brand Name Master Long Form Complaint vs GlaxoSmith 5-31-2016.pdf
  8. ZOFRAN MDL 2657 MDL Generic Name Master Long Form Complaint vs Novartis - GlaxoSmith 5-31-2016.pdf
  9. ZOFRAN MDL 2657 MDL (2nd order) Approved Generic Joint Master Short Form Complaint 6-20-2016.pdf
  10. ZOFRAN MDL 2657 MDL Approved Generic Joint Master Short Form Complaint 6-20-2016.pdf
  11. ZOFRAN MDL 2657 MDL Brand Name Master Long Form Complaint vs GlaxoSmith 5-31-2016.pdf
  12. ZOFRAN MDL 2657 MDL Generic Name Master Long Form Complaint vs Novartis - GlaxoSmith 5-31-2016.pdf
  13. CMO 1 Waiver of Pro Hac and Other Filing Instructions.pdf
  14. CMO 2 Appearance of Counsel by Telephone.pdf
  15. CMO 3 Appointing Lead Counsel.docx
  16. CMO 3 Appointing Lead Counsel.pdf
  17. CMO 4 Stay.pdf
  18. CMO 5 Appearance of Counsel Order.pdf
  19. CMO 6 Direct Filing Order.pdf
  20. CMO 7 Waiver of Service.pdf
  21. Zofran MDL CMO 8 Appointing Leadership.docx
  22. 01- Defedants Motion to Consolidate and Transfer.pdf
  23. 01-1.pdf
  24. 01-2.pdf
  25. 01-3.pdf
  26. 01-4.pdf
  27. 01-5.pdf
  28. 01-6.pdf
  29. 01-7.pdf
  30. 01-8.pdf
  31. 01-9.pdf
  32. 01-10.pdf
  33. 01-11.pdf
  34. 01-12.pdf
  35. 01-13.pdf
  36. 01-14.pdf
  37. 01-15.pdf
  38. 01-16.pdf
  39. D-Teratogens.mp4
  40. First and Second Generation Antidepressants.mp4
  41. How to Pronounce Teratogen.mp4
  42. How to Pronounce Teratogenesis.mp4
  43. How to Pronounce Teratogenic.mp4
  44. How to Pronounce Teratogenicity.mp4
  45. How to Pronounce Teratogens.mp4
  46. Human Teratology Maternal and Fetal Drug Disposition (2).mp4
  47. SSRIs and New Antidepressants.mp4
  48. The 5-HT3 Receptors and Antiemetics Part 1.mp4
  49. The 5-HT3 Receptors and Antiemetics Part 2.mp4
  50. The 5-HT3 Receptors and Antiemetics Part 3.mp4
  51. The 5-HT3 Receptors and Antiemetics Part 4.mp4
  52. The 5-HT3 Receptors and Depression Part 1.mp4
  53. The 5-HT3 Receptors and Depression Part 2.mp4
  54. The 5-HT3 Receptors and Depression Part 3.mp4
  55. The 5-HT3 Receptors and Depression Part 5.mp4
  56. The Chemical Mind - Crash Course Psychology 3.mp4
  57. The first trimester Fetal development week by week.mp4
  58. Zofran birth defects.mp4
  59. The Chemical Mind - Crash Course Psychology 3.mp4
  60. The first trimester Fetal development week by week.mp4
  61. The second trimester Fetal development week by week.mp4
  62. What is 287.mp4
  63. Zofran for morning sickness.mp4
  64. 5 HT Uptake Inhibitors.pdf
  65. American Jounal of Obsterics Artilce.pdf
  66. Article on Med Guides vs Prescribing Info.pdf
  67. Birth Defect Statistics.docx
  68. FDA Seritonin Syndrome.pdf
  69. How are Medication Guides different from Consumer Medication Information.docx
  70. Mantel-Haenszel_Test.pdf
  71. Midline Birth Defects Americal Journal.pdf
  72. National Birth Defects Prevention Study 2013.pdf
  73. National Birth Defects Prevention Study.pdf
  74. New England Journal Zofran.docx
  75. PDUFA FY 2012 Performance Report_(Section 508 ready_5-17-13).pdf
  76. State SOL Minors.xlsx
  77. Swedish Study.docx
  78. Swedish Study.pdf
  79. Zofran 2014-Koren-Ondansetron-Safety-TDM.pdf
  80. Zofran FDA Approval.pdf
  81. Zofran Prescribing Information 2.pdf
  82. Zofran Prescribing Information.pdf
  83. Zofran Warning 2013.docx
  84. Zuplenz Prescribing Information.pdf
  85. 2013-Pharmacoepidemiology_and_Drug_Safety.pdf
  86. State SOL Minors.xlsx
  87. Zofran MDL Registration for Electronic Filing
  88. Judge Dennis Saylor.docx
  89. Zofran Judge Saylor Standing Order Motions Practice etc.pdf
  90. Zofran Judge Saylor Standing Order Inexperienced Attorneys.pdf
  91. Zofran Judge Saylor Standing Order.pdf
  92. Zofran MDL 2657 Transferee Court Attorney Handbook.pdf
  93. Zofran Transferee Court Local Rules.pdf
  94. Zofran MDL 2657 Transferee Court Phone Directory.pdf
  95. Zofran MDL 2657 Consent Order of Transferee Judge.pdf
  96. Zofran MDL 2657 JPML Transfer Order 10-13-2015.pdf
  97. Zofran Judge Saylor Standing Order Motions Practice etc.pdf
  98. Zofran MDL 2657 Transferee Court Attorney Handbook.pdf
  99. Zofran Transferee Court Local Rules.pdf
  100. Zofran MDL 2657 Transferee Court Phone Directory.pdf
  101. State SOL Tolling For Minors.xlsx
  102. Flynn v Glaxo Eastern District of Pennsylvania 02-12-2015.pdf
  103. Flynn v Glaxo Eastern District of Pennsylvania 02-12-2015.docx
  104. LeClair v Glaxo District of Massachuetts 02-13-2015.pdf
  105. LeClair v Glaxo District of Massachuetts 02-13-2015.docx
  106. Casey v Glaxo District of Montana 04-03-2015.docx
  107. Casey v Glaxo District of Montana 04-03-2015.pdf
  108. Doc 01-8 Complaint Eastern District of Louisana.docx
  109. Doc 01-8 Complaint Eastern District of Louisana.pdf
  110. DOC 01-14 Zofran Norther District Ohio.pdf
  111. Doc 01-15 Zofran Complaint Eastern District Tx.docx
  112. Doc 01-15 Zofran Complaint Eastern District Tx.pdf
  113. Doc 109- Zofran Notice of Tag Along Actions.pdf
  114. Doc 109-1 Schdule of Actions.pdf
  115. Doc 109-2 Certificate of Service.pdf
  116. Doc 109-3 Zofran Complaint California Central.docx
  117. Doc 109-3 Zofran Complaint California Central.pdf
  118. Doc 109-3 Zofran Complaint California.docx
  119. Doc 109-3 Zofran Complaint California.pdf
  120. Doc 109-4 Zofran Complaint New Jersey.docx
  121. Doc 109-4 Zofran Complaint New Jersey.pdf
  122. Doc 109-5 Zofran Complaint Eastern District of KY.docx
  123. Doc 109-5 Zofran Complaint Eastern District of KY.pdf
  124. Doc 109-6 Zofran Complaint Northern District CA.docx
  125. Doc 109-6 Zofran Complaint Northern District CA.pdf
  126. Doc 109-7 Zofran Complaint Orther District of CA.docx
  127. Doc 109-7 Zofran Complaint Orther District of CA.pdf
  128. Alexander_v_GSK-2_15-cv-02323-atrial-septal-defect-zofran-lawsuit-complaint.pdf
  129. Botelho_v_GSK-1_15-cv-13002-FDS-TGV-zofran-lawsuit-complaint.pdf
  130. Coughlinetal-v-GSK-15-815-joined-zofran-lawsuit-complaint (2).pdf
  131. Duong-v-GSK-1_15-11627-abdominal-malformation-zofran-lawsuit-complaint.pdf
  132. 53-1 Plaintiffs Motion Leadership Positions.pdf
  133. 53-2 Plaintiffs Motion Leadership Positions.pdf
  134. 53-3 Plaintiffs Motion Leadership Positions.pdf
  135. 53-4 Plaintiffs Motion Leadership Positions.pdf
  136. 53-5 Plaintiffs Motion Leadership Positions.pdf
  137. 53-6 Plaintiffs Motion Leadership Positions.pdf
  138. 53-7 Plaintiffs Motion Leadership Positions.pdf
  139. 53-8 Plaintiffs Motion Leadership Positions.pdf
  140. 53-9 Plaintiffs Motion Leadership Positions.pdf
  141. 53-10 Plaintiffs Motion Leadership Positions.pdf
  142. 53-11 Plaintiffs Motion Leadership Positions.pdf
  143. 53-12 Plaintiffs Motion Leadership Positions.pdf
  144. 53-13 Plaintiffs Motion Leadership Positions.pdf
  145. 53-14 Plaintiffs Motion Leadership Positions.pdf
  146. 53-15 Plaintiffs Motion Leadership Positions.pdf
  147. 96-1 Exhibit Defendants Motion to Dismiss.pdf
  148. 96-2 Exhibit Defendants Motion to Dismiss.pdf
  149. 96-3 Exhibit Defendants Motion to Dismiss.pdf
  150. 96-4 Exhibit Defendants Motion to Dismiss.pdf
  151. 96-5 Exhibit Defendants Motion to Dismiss.pdf
  152. 96-6 Exhibit Defendants Motion to Dismiss.pdf
  153. Application of Elizabeth Graham Lead Counsel.pdf
  154. Application of Kimberly Barone Baden Lead Counsel.pdf
  155. Application of Robert Jenner Liason Counsel.pdf
  156. Application of Tobias Millrod Lead Counsel.pdf
  157. Application to Serve as Leade Counsel.pdf
  158. Civil Cover Sheet (2).pdf
  159. Civil Cover Sheet.pdf
  160. CMO 1 Waiver of Pro Hac and Other Filing Instructions.pdf
  161. CMO 2 Appearance of Counsel by Telephone.pdf
  162. CMO 3 Appointing Lead Counsel.docx
  163. CMO 3 Appointing Lead Counsel.pdf
  164. CMO 4 Stay.pdf
  165. CMO 5 Appearance of Counsel Order.pdf
  166. CMO 6 Direct Filing Order.pdf
  167. CMO 7 Waiver of Service.pdf
  168. Complaint.pdf
  169. CTO 1.pdf
  170. CTO 2.pdf
  171. CTO 3.pdf
  172. CTO 4.pdf
  173. CTO 5.pdf
  174. CTO 6.pdf
  175. CTO 7.pdf
  176. CTO 8.pdf
  177. CTO 9.pdf
  178. Dec 16 2015 Conference Agenda.pdf
  179. Defendants Motion to Dismiss See Also Notice of FDA Action.pdf
  180. Defendants Motion to Dismiss for Failure to State a Claim.pdf
  181. Defendants Proposed Status Conference Agenda Nov 2015.pdf
  182. JPML Transfer Order.pdf
  183. Motion for the Appointment of Steering Committee.pdf
  184. Notice of FDA Action Exhibit Important.pdf
  185. Notice of FDA Regulator Action Important.pdf
  186. Plaintiffs Motion Leadership Positions.pdf
  187. Proposed MDL Order Appointing Lead Counsel.pdf
  188. Remand Order Back to State.pdf
  189. Stipulated Ext of Time to File Answer.pdf
  190. Transfer Order.pdf
  191. Zofran JPML Hearing Jan 2016.pdf
  192. Zofran MDL CMO 8 Appointing Leadership.docx
  193. Zofran MDL CMO 8 Appointing Leadership.pdf
  194. Defendant Memo Support Motion Product ID Ex B.pdf
  195. Defendant Memo Support Motion Product ID Ex A.pdf
  196. Defendant Memo Support Motion Product ID Ex C.pdf
  197. Defendant Memo Support Motion Product ID Ex D.pdf
  198. Defendant Memo Support Motion Product ID Ex E.pdf
  199. Defendant Memo Support Motion Product ID.pdf
  200. Defendants Memo of Law Protected Discovery.pdf
  201. Defendants Memo of Law Opposing Remand.pdf
  202. Defendants Motion For Order Product ID.pdf
  203. Deny Defendants Motion to Dismiss on Preemption.pdf
  204. EX A Defendants Memo of Law Opposing Remand.pdf
  205. Plaintiffs Proposal for Master Complaint.pdf
  206. Proposed Order Concerning Discovery.pdf
  207. Proposed Order Master Complaint and Fact Sheets.pdf
  208. Zofran Complaint Example March 2016 Civil Cover Sheet.pdf
  209. Zofran Complaint Example March 2016 Cover.pdf
  210. Zofran Complaint Example March 2016.pdf
  211. Stipulated Dismissal of Single Case -Settlement.pdf
  212. Zofran Defendants Respone to Plaintiffs SJM Answer.pdf
  213. Zofran Plaintiffs Reponse to Defendants SJM.pdf
  214. Zofran Plaintiffs Response to SJM Exhibit.pdf
  215. Zofran Order Denying Defendants Summary Motion.pdf
  216. Defendants Motion to Dismiss See Also Notice of FDA Action.pdf
  217. Defendants Motion to Dismiss for Failure to State a Claim.pdf
  218. 96-1 Exhibit Defendants Motion to Dismiss.pdf
  219. 96-2 Exhibit Defendants Motion to Dismiss.pdf
  220. 96-3 Exhibit Defendants Motion to Dismiss.pdf
  221. 96-4 Exhibit Defendants Motion to Dismiss.pdf
  222. 96-5 Exhibit Defendants Motion to Dismiss.pdf
  223. 96-6 Exhibit Defendants Motion to Dismiss.pdf
  224. Notice of FDA Action Exhibit Important.pdf
  225. Notice of FDA Regulator Action Important.pdf
  226. Zofran MDL Master Case File Number.docx
View All

Discussion

    No Recent Messages
Add Comment